Last reviewed · How we verify
AFT Pharmaceuticals, Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Maxigesic IV | Maxigesic IV | phase 3 | Fixed-dose combination analgesic/NSAID | Prostaglandin synthesis inhibitors (COX-1, COX-2, and central pain pathways) | Pain Management | |
| Combogesic® tablets | Combogesic® tablets | phase 3 | Fixed-dose combination analgesic/NSAID | COX-1, COX-2 (ibuprofen); central pain pathways (paracetamol) | Pain Management |
Therapeutic area mix
- Pain Management · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Universidade Estadual de Ponta Grossa · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for AFT Pharmaceuticals, Ltd.:
- AFT Pharmaceuticals, Ltd. pipeline updates — RSS
- AFT Pharmaceuticals, Ltd. pipeline updates — Atom
- AFT Pharmaceuticals, Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). AFT Pharmaceuticals, Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aft-pharmaceuticals-ltd. Accessed 2026-06-09.